Medication info
Seviterahct Tablet 5/40/12.5 Milligrams

Seviterahct Tablet 5/40/12.5 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Amlodipine Besylate›6.944mg / 1 tabletOlmesartan Medoxomil›40mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Teragen Etex Co., Ltd.
Appearance
Pale yellow round film-coated tablet
Packaging
28 tablets (14 tablets/PTP x 2)/ carton
Approval status
Active

MFDS item code 201805304 · Approved 2018.12.27 · Insurance code 698503950

Summary

Main use
Treatment of essential hypertension not controlled with combination therapy
Who takes it
Adults · Children
Adult dose
Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take this medicine at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended that the dose of each individual component (olmesartan medoxomil and amlodipine, as monotherapy or combination therapy) be adjusted. However, if blood pressure is not controlled with combination therapy of amlodipine and olmesartan medoxomil, switching directly to this medicine may be considered as follows. The maximum dose of this medicine is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. Because the maximum blood pressure-lowering effect occurs within 2 weeks after administration, adjust the dose at intervals of 2 weeks or longer, taking the patient’s blood pressure response into consideration. The recommended doses are as follows. - 5/20/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or with this medicine 5/20/12.5mg. - 5/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/12.5mg. - 10/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or with this medicine 5/40/12.5mg. - 10/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/25mg or this medicine 10/40/12.5mg. ※ Refer to the following dose escalation diagram. (The amounts of each component are listed in the order amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg Patients with renal impairment The maximum dose of this medicine for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5 milligrams once daily. For patients with moderate renal impairment, monitoring of potassium and creatinine levels is recommended. Do not administer this medicine to patients with severe renal impairment (creatinine clearance < 30mL/min). Patients with hepatic impairment Use with caution in patients with mild or moderate hepatic impairment. The maximum dose of this medicine for patients with moderate hepatic impairment is 5/20/12.5 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. Do not administer this medicine to patients with severe hepatic impairment. Older adults (65 years or older) In general, initiate treatment at a low dose. When adjusting the dose, consider the patient’s renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in older adults. Because there is very limited experience with the use of this medicine in older adults aged 75 years or older, monitor very carefully when administering this medicine.
Child dose
The safety and efficacy of this medicine in pediatric patients under 18 years of age have not been established; therefore, its use is not recommended.

Ingredients

Manufacturer
Teragen Etex Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with combination therapy

  • Essential hypertension
View approved original text

Amlodipine and Olmesartan Medoxomil are medications used to effectively manage blood pressure in patients with essential hypertension. When these two drugs are used in combination, each component helps to dilate blood vessels and improve blood circulation, thereby assisting in lowering blood pressure. Combination therapy is applied when control of blood pressure is difficult with a single drug, aiming for more stable management of blood pressure. This treatment contributes to protecting the cardiovascular health of the patient and reduces the risk of complications from hypertension. Thus, the combination therapy of Amlodipine and Olmesartan Medoxomil is used for effective blood pressure control in essential hypertension.

How to take

Adult dose

Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take this medicine at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended that the dose of each individual component (olmesartan medoxomil and amlodipine, as monotherapy or combination therapy) be adjusted. However, if blood pressure is not controlled with combination therapy of amlodipine and olmesartan medoxomil, switching directly to this medicine may be considered as follows. The maximum dose of this medicine is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. Because the maximum blood pressure-lowering effect occurs within 2 weeks after administration, adjust the dose at intervals of 2 weeks or longer, taking the patient’s blood pressure response into consideration. The recommended doses are as follows. - 5/20/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or with this medicine 5/20/12.5mg. - 5/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/12.5mg. - 10/40/12.5mg: For patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or with this medicine 5/40/12.5mg. - 10/40/25mg: For patients whose blood pressure is not adequately controlled with this medicine 5/40/25mg or this medicine 10/40/12.5mg. ※ Refer to the following dose escalation diagram. (The amounts of each component are listed in the order amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg Patients with renal impairment The maximum dose of this medicine for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5 milligrams once daily. For patients with moderate renal impairment, monitoring of potassium and creatinine levels is recommended. Do not administer this medicine to patients with severe renal impairment (creatinine clearance < 30mL/min). Patients with hepatic impairment Use with caution in patients with mild or moderate hepatic impairment. The maximum dose of this medicine for patients with moderate hepatic impairment is 5/20/12.5 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. Do not administer this medicine to patients with severe hepatic impairment. Older adults (65 years or older) In general, initiate treatment at a low dose. When adjusting the dose, consider the patient’s renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in older adults. Because there is very limited experience with the use of this medicine in older adults aged 75 years or older, monitor very carefully when administering this medicine.

Child dose

The safety and efficacy of this medicine in pediatric patients under 18 years of age have not been established; therefore, its use is not recommended.

Precautions

This drug may cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy; therefore, it should be stopped immediately upon confirmation of pregnancy. This drug is contraindicated in patients with allergies to this drug or its components, as well as those with certain heart, kidney, or liver diseases, pregnant and nursing women, and patients with certain electrolyte abnormalities. Do not administer to patients with very low blood pressure, acute heart failure, severe liver dysfunction, or kidney dysfunction. Patients with reduced blood volume or those sensitive to changes in kidney function should be closely monitored before administration and appropriate measures taken if necessary. This drug should be used with caution in patients with impaired kidney function, those with specific cardiac valve diseases, liver dysfunction, and elderly patients. Since this drug lowers blood pressure, caution should be taken as dizziness or drowsiness may occur when driving or operating machinery. During the administration of this drug, serum electrolyte concentrations and kidney function should be regularly monitored to ensure no abnormalities are present. This drug may interact with other medications, especially when taken with lithium, non-steroidal anti-inflammatory drugs, or other antihypertensives, so consultation with a physician or pharmacist is necessary. Use should be avoided during pregnancy as it may pose risks to the fetus, and lactating women may need to stop breastfeeding or discontinue the drug as its ingredients can be transferred through breast milk. Safety and efficacy in pediatric patients have not been established, so its use is not recommended. In case of overdose, symptoms like hypotension, palpitations, and bradycardia may occur, and immediate medical attention should be sought for appropriate treatment. This drug should be stored in a cool, dry place away from moisture and heat, and kept out of reach of children.

Side effects

Peripheral edema, headache, dizziness, upper respiratory tract infection, nasopharyngitis, urinary tract infection, sialadenitis, leukopenia, thrombocytopenia, bone marrow suppression, neutropenia, agranulocytosis, hemolytic anemia, aplastic anemia, anaphylactic reaction, drug hypersensitivity, hyperkalemia, hypokalemia, anorexia, diabetes, hypercalcemia, hyperglycemia, hypomagnesemia, hyponatremia, hypochloremia, hypertriglyceridemia, hypercholesterolemia, hyperuricemia, hypochloremic alkalosis, hyperamylasemia, confusion, depression, apathy, hypersensitivity, agitation, mood changes, sleep disorders, orthostatic dizziness, syncope, dysgeusia, hypertonia, sensory impairment, paresthesia, peripheral neuropathy, drowsiness, fainting, seizures, loss of appetite, tremor, visual disturbances, reduced tear production, worsening of myopia, jaundice, vertigo, tinnitus, palpitations, tachycardia, myocardial infarction, arrhythmia, angina, hypotension, flushing, orthostatic hypotension, vasculitis, thrombosis, embolism, cough, bronchitis, dyspnea, pharyngitis, rhinitis, acute interstitial pneumonia, respiratory distress syndrome, pulmonary edema, diarrhea, nausea, constipation, dry mouth, abdominal pain, changes in bowel habits, distension, dyspepsia, gastritis, gastric discomfort, gastroenteritis, gingival hyperplasia, paralytic ileus, pancreatitis, vomiting, hepatitis, jaundice, acute cholecystitis, autoimmune hepatitis, hair loss, angioedema, allergic dermatitis, erythema multiforme, erythema, skin lupus erythematosus-like reaction, pustular rash, exfoliative dermatitis, hyperhidrosis, phototoxic reaction, pruritus, purpura, Quincke's edema, rash, recurrence of skin lupus erythematosus, toxic skin necrosis, skin discoloration, Stevens-Johnson syndrome, urticaria, muscle spasms, joint swelling, muscle weakness, ankle edema, arthralgia, arthritis, low back pain, paresis, myalgia, bone pain, polyuria, acute renal failure, hematuria, urinary dysfunction, nocturia, interstitial nephritis, renal failure, erectile dysfunction, gynecomastia, asthenia, fatigue, chest pain, fever, influenza-like symptoms, lethargy, malaise, edema, pain, facial swelling, increased serum creatinine, increased serum urea, increased serum uric acid, decreased serum potassium, increased gamma-glutamyl transferase, increased alanine aminotransferase, increased aspartate aminotransferase, increased liver enzymes, increased serum creatinine phosphokinase, weight loss, weight gain, rhabdomyolysis, chronic malabsorption, intestinal vascular edema, drug hypersensitivity, upper abdominal pain, decreased libido, anasarca, asthenia, altered consciousness, eczema, limb pain, mild decrease in average hemoglobin and hematocrit levels, dizziness, benign prostatic hyperplasia, benign salivary gland neoplasm, cerebral infarction, renal failure, abdominal bloating, facial flushing, epistaxis, prostatic hyperplasia, prostatitis, dysphagia, papular rash, renal cell dysplasia, acute hearing loss, lymphadenitis, acute respiratory distress syndrome

Not everyone experiences these, and they can vary from person to person.

Storage

This drug may be sensitive to air or moisture, so it must be stored in a tightly closed container. It is best to maintain a storage temperature between 1 degree and 30 degrees Celsius to preserve the medication's effectiveness.

Appearance and packaging

Appearance

Pale yellow round film-coated tablet

Package unit

28 tablets (14 tablets/PTP x 2)/ carton

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.